Stapled peptide-based membrane fusion inhibitors of hepatitis C virus

被引：60
|
作者：
Cui, Hong-Kui [1 ]
Qing, Jie [1 ]
Guo, Ye [1 ]
Wang, Yu-Jia [1 ]
Cui, Li-Jia [2 ,3 ]
He, Tian-Hua [2 ,3 ]
Zhang, Linqi [2 ,3 ]
Liu, Lei [1 ]
机构：
[1] Tsinghua Univ, Dept Chem, Tsinghua Peking Ctr Life Sci,Minist Educ, Key Lab Bioorgan Phosphorus Chem & Chem Biol, Beijing 100084, Peoples R China
[2] Tsinghua Univ, Sch Med, Comprehens AIDS Res Ctr, Beijing 100084, Peoples R China
[3] Tsinghua Univ, Sch Med, Res Ctr Publ Hlth, Beijing 100084, Peoples R China
来源：
BIOORGANIC & MEDICINAL CHEMISTRY | 2013年 / 21卷 / 12期
基金：
中国国家自然科学基金;
关键词：
Hepatitis C virus; Stapled peptide; Protein-protein interaction; CELL-CULTURE SYSTEMS; B TYPE-I; OLEFIN METATHESIS; ALPHA-HELICES; BH3; HELIX; CD81; ENTRY; INFECTION; PROTEINS; RECEPTOR;
D O I：
10.1016/j.bmc.2013.02.011
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The strategy of peptide stapling was used to develop new molecules to inhibit the hepatitis C virus infection via disrupting the binding of HCV envelope glycoprotein E2 with human cell surface protein CD81. The peptide sequence was designed based on the large extra-cellular loop of CD81 with known importance in the HCV E2 binding interaction. Our results showed that the stapled peptides exhibited significantly higher alpha-helicity and proteolytic stability as compared to their linear peptide counterpart. The optimal compound was found to have an EC50 value of ca. 17-39 mu M against different HCV subtypes and represented a new HCV membrane fusion inhibitor. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码：3547 / 3554
页数：8
相关论文
共 50 条
  • [11] Flunarizine arrests hepatitis C virus membrane fusion
    Prigozhin, Daniil M.
    Modis, Yorgo
    HEPATOLOGY, 2016, 63 (01) : 14 - 16
  • [12] Peptide inhibitors of hepatitis C virus core oligomerization and virus production
    Kota, S.
    Coito, C.
    Mousseau, G.
    Lavergne, J. -P.
    Strosberg, A. D.
    JOURNAL OF GENERAL VIROLOGY, 2009, 90 : 1319 - 1328
  • [13] Stapled Peptides-A Useful Improvement for Peptide-Based Drugs
    Moiola, Mattia
    Memeo, Misal G.
    Quadrelli, Paolo
    MOLECULES, 2019, 24 (20):
  • [14] Peptide-based entry inhibitors for paramyxoviruses
    LeBlanc, Christopher
    Wilson, Russell
    Kulkosky, Peter
    Garry, Robert
    Voss, Thomas
    ANTIVIRAL RESEARCH, 2008, 78 (02) : A43 - A43
  • [15] Peptide-based entry inhibitors for influenza
    Voss, Thomas
    LeBlanc, Christopher
    Barbercheck, Joseph
    Kaplan, Bryan
    Wilson, Russell
    Robert, Garry
    ANTIVIRAL RESEARCH, 2008, 78 (02) : A18 - A18
  • [16] Peptide-based inhibitors of amyloid assembly
    Sciarretta, Kimberly L.
    Gordon, David J.
    Meredith, Stephen C.
    AMYLOID, PRIONS, AND OTHER PROTEIN AGGREGATES, PT C, 2006, 413 : 273 - 312
  • [17] Peptide-based inhibitors of hepatitis C virus full-length NS3 (protease-helicase/NTPase): Model compounds towards small molecule inhibitors
    Oscarsson, K
    Poliakov, A
    Oscarson, S
    Danielson, UH
    Hallberg, A
    Samuelsson, B
    BIOORGANIC & MEDICINAL CHEMISTRY, 2003, 11 (13) : 2955 - 2963
  • [18] Stapling patten influences the in vivo fate of stapled peptide-based radiotracers
    Tian, Hao
    Liu, Xiangding
    Zhang, Siqi
    Wang, Xingkai
    Huang, Hongyi
    Jiang, Shuo
    Wang, Rui
    Hu, Kuan
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [19] Developing peptide-based fusion inhibitors as an antiviral strategy utilizing coronin 1 as a template
    Panda, Manbit Subhadarsi
    Qazi, Bushra
    Vishwakarma, Vaishali
    Pattnaik, Gourab Prasad
    Haldar, Sourav
    Chakraborty, Hirak
    RSC MEDICINAL CHEMISTRY, 2025, 16 (01): : 125 - 136
  • [20] Peptide-based inhibitors of the phagocyte NADPH oxidase
    El-Benna, Jamel
    Dang, Pham My-Chan
    Perianin, Axel
    BIOCHEMICAL PHARMACOLOGY, 2010, 80 (06) : 778 - 785
12345